21 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
27 Oct 15
Current report (foreign)
12:00am
demonstrated,” Dr. Megiddo concluded.
“The OPMD community currently has very limited treatment options and there is a critical unmet need for patients … patient community.
About BioBlast
BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
12 Sep 22
Report of Foreign Private Issuer
8:02am
to discussing our findings with the medical community at this year’s congress.”
Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
whose infection source was urinary tract, 68% for patients whose infection source was community-acquired pneumonia, and 36% for patients whose
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
was urinary tract (UTI), 68% for patients whose infection source was community - acquired pneumonia, and 36% for patients whose infection source
20-F
6y3 7kvjd
31 Mar 15
Annual report (foreign)
12:00am
F-1/A
55e53
8 Jul 14
Registration statement (foreign) (amended)
12:00am
424B4
6bd 86z9vu1o883l
31 Jul 14
Prospectus supplement with pricing info
12:00am
424B3
g34n9
10 Jul 19
Prospectus supplement
8:18am
F-3
9fphg p7kciqk729h8m
28 Jun 19
Shelf registration (foreign)
9:48am
424B5
f4ge8i
26 Feb 20
Prospectus supplement for primary offering
8:23am
424B5
5wr 7hxxlmj86ju
3 Mar 20
Prospectus supplement for primary offering
5:13pm